AI's Visionary Leap: How Offline Tech Is Saving Sight in Rural India

NEW DELHI – June 26, 2026 – In a move that signals a powerful fusion of corporate strategy and public health, healthtech startup Artelus has been named the winner of the Drishti HealthTech Challenge, an initiative by Roche Pharma India and the government's Startup India program. The company secured a financial grant of INR 35 lakhs for its groundbreaking AI platform designed to screen for Diabetic Retinopathy, a leading cause of preventable blindness. But this story is about more than a startup competition; it’s about a fundamental shift in how we can tackle systemic health crises by building systems that reach the most vulnerable.

At the heart of this win is a piece of technology that addresses a core challenge in Indian healthcare: the last mile. For millions living in remote corners of the country, access to specialized diagnostics is a luxury they cannot afford. Artelus’s solution directly confronts this reality, promising to bring sight-saving screening to populations that have, until now, been left in the dark.

The Last Mile of Diagnosis: AI That Works Offline

Diabetic Retinopathy (DR) is a complication of diabetes that damages the blood vessels in the retina. If caught early, vision loss is largely preventable. If not, it leads to irreversible blindness. The challenge has always been detection. Traditional screening requires expensive equipment and a trained ophthalmologist to interpret the images—resources that are heavily concentrated in urban centers.

Artelus’s winning innovation, DRISTi (Diabetic Retinopathy Screening), dismantles this barrier with a one-of-a-kind 'AI on a Chip.' This technology enables fully offline retinal screening, functioning entirely without internet or cloud connectivity. The AI algorithms are embedded in a portable device, allowing a minimally trained health worker to conduct a comprehensive retinal scan in a village, a local clinic, or even a person's home. The system provides an instantaneous analysis, classifying the severity of DR and flagging cases that require urgent referral to a specialist.

“Retinal diseases are stealing sight across India,” said Rajji Mehdwan, Roche Pharma India’s Managing Director & CEO. “What we didn't have was a way to make early diagnosis accessible to everyone. Artelus solves that. Their offline AI technology brings screening to places we've never been able to reach before—expanding access to a much wider group of people. That changes everything.”

The platform's intelligence is not just about a simple yes-or-no diagnosis. It can identify various stages of Diabetic Retinopathy, Diabetic Macular Edema, and even provide a risk assessment for glaucoma. This level of detail, delivered instantly and offline, empowers local healthcare providers to make informed decisions, ensuring that only those who truly need specialist care undertake the often-long and costly journey to a city hospital.

A Looming Crisis: India's Battle Against Diabetic Blindness

The urgency for a solution like DRISTi cannot be overstated. India is often referred to as the diabetes capital of the world, with an estimated 77 million adults living with the condition—a number projected to soar to over 134 million by 2045. The prevalence of Diabetic Retinopathy among this population is alarmingly high, with studies indicating that nearly one in five people with diabetes in India has the condition. This translates to millions of people at risk of losing their sight.

The public health system, despite its best efforts, has struggled to keep pace. The urban-rural divide in healthcare infrastructure is stark. A lack of awareness among patients, coupled with the scarcity of trained ophthalmologists and screening equipment in remote areas, means that most cases of DR are diagnosed too late, when treatment options are limited and vision loss is already significant.

Innovations like DRISTi represent a paradigm shift from a reactive, hospital-centric model to a proactive, community-based system of care. By democratizing the tool of diagnosis, it empowers the existing healthcare workforce and creates a scalable framework for tackling a public health crisis at its roots.

Building a System for Success: The Power of Partnership

Artelus’s victory is a testament not only to its technology but also to the power of a well-designed collaborative ecosystem. The Drishti HealthTech Challenge, a joint initiative by the Department for Promotion of Industry and Internal Trade (DPIIT) and Roche Pharma India, is a model for how public policy and corporate responsibility can converge to foster meaningful innovation.

The award ceremony, held at the Swiss Embassy in New Delhi, underscored the international dimension of this partnership. Her Excellency, Mrs. Maya Tissafi, Ambassador of Switzerland to India and Bhutan, noted, “The Trade and Economic Partnership Agreement between EFTA and India has intensified the economic relationship between our countries. It creates a ground for exactly the kind of innovation we see today.”

For Roche, a global pharmaceutical leader, the initiative is a strategic investment in the future of healthcare. The INR 35 lakhs grant and the subsequent partnership to co-develop and pilot the solution provide Artelus with not just capital, but also the invaluable expertise, and market access of a global giant. For the government, it is a validation of its efforts to build a thriving startup culture.

“Fostering an ecosystem where advanced technology seamlessly integrates with grassroots healthcare delivery is key to sustainable economic development,” said Shri Ateesh Kumar Singh, Additional Secretary, DPIIT. “Startup India, DPIIT remains committed to supporting open innovation frameworks that empower homegrown entrepreneurs to scale their impact across the country.”

This collaborative structure ensures that a brilliant idea doesn't just remain an idea. It provides the financial, technical, and logistical support needed to translate a prototype into a population-scale solution. As Girish Somvanshi, Co-Founder & VP of Artelus, put it, “At Artelus, we are building the infrastructure to ensure every patient is identified, referred, treated, and followed up - at a population scale optimized for India and the rest of the world.”

A Bellwether for Homegrown Innovation

Beyond the immediate impact on eye care, the story of Artelus and the Drishti Challenge reflects a broader maturation of India’s healthtech landscape. The country is now home to over 14,000 healthtech companies, making it one of the largest and fastest-growing digital health ecosystems in the world. Government initiatives like Startup India and the Ayushman Bharat Digital Mission have created a fertile ground for entrepreneurs to build solutions tailored to India's unique challenges.

These are not just copies of Western models; they are homegrown innovations designed for affordability, scalability, and resilience in low-resource settings. Artelus’s focus on an offline-first solution is a prime example of this context-aware design. The success of such ventures is creating a powerful narrative: India is no longer just a market for technology, but a creator of it.

The partnership between a local startup, a global corporation, and the national government provides a powerful blueprint for the future. It demonstrates how targeted investment and strategic collaboration can unlock the potential of technology to build more equitable and resilient systems, ensuring that the benefits of progress reach everyone, one screening at a time.